palbociclib – SOLTI

1 de June de 2024

A new chemotherapy-free combination reduces the risk of progression by 48% and improves tolerability in a molecularly selected group of patients with advanced breast cancer

In patients with ER+/HER2+ metastatic breast cancer of luminal subtype A or B, combined treatment with hormone therapy, trastuzumab and palbociclib significantly delays the time to […]

15 de May de 2024

SOLTI launches AI-based tool to avoid toxicities in the treatment of hormonal breast cancer patients

Cyclibtool platform allows the oncologist to find out about drug interactions between the most common treatments with each of the different cyclin inhibitors (CDK 4/6) approved […]